UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

Molecular medicine (Cambridge, Mass.), 2021-05, Vol.27 (1), p.48-48, Article 48

2021

Volltextzugriff (PDF)

High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Molecular medicine (Cambridge, Mass.), 2014, Vol.20 (1), p.538-547

2014

Volltextzugriff (PDF)

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Molecular medicine (Cambridge, Mass.), 2020-12, Vol.26 (1), p.131-131, Article 131

2020

Volltextzugriff (PDF)

Expression of concern to: High systematic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Molecular medicine (Cambridge, Mass.), 2020-02, Vol.26 (1), p.1-1, Article 17

2020

Volltextzugriff (PDF)

Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study

Pediatric rheumatology online journal, 2021-12, Vol.19 (1), p.173-173, Article 173

2021

Volltextzugriff (PDF)

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Blood, 2019-06, Vol.133 (23), p.2465-2477

2019

Volltextzugriff (PDF)

Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study

Blood, 2017-12, Vol.130 (25), p.2728-2738

2017

Volltextzugriff (PDF)

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

Annals of the rheumatic diseases, 2016-03, Vol.75 (3), p.481-489

2016

Volltextzugriff (PDF)

Juvenile idiopathic arthritis, marriage and parenthood: a nationwide matched cohort study

Rheumatology (Oxford, England), 2022-03, Vol.61 (3), p.1228-1232

2022

Volltextzugriff (PDF)

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

Blood, 2011-10, Vol.118 (17), p.4577-4584

2011

Volltextzugriff (PDF)

Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis

Annals of the rheumatic diseases, 2019-10, Vol.78 (10), p.1357

2019

Volltextzugriff (PDF)

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

Pediatric Blood & Cancer, 2007-02, Vol.48 (2), p.124-131

2007

Volltextzugriff (PDF)

Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2018-09, Vol.6 (5), p.1508-1517

2018

Volltextzugriff (PDF)

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration

PloS one, 2023-12, Vol.18 (12), p.e0295838

2023

Volltextzugriff (PDF)

A Two-to-Five Year Follow-Up of a Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort

Child psychiatry and human development, 2022-04, Vol.53 (2), p.354-364

2022

Volltextzugriff (PDF)

How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Current treatment options in neurology, 2017, Vol.19 (1), p.3-3, Article 3

2017

Volltextzugriff (PDF)

Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

The Journal of pediatrics, 2017-10, Vol.189, p.72-78.e3

2017

Volltextzugriff (PDF)

Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis

British journal of haematology, 2008-02, Vol.140 (3), p.327-335

2008

Volltextzugriff (PDF)

Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children

The Lancet regional health. Europe, 2022-08, Vol.19, p.100443-100443, Article 100443

2022

Volltextzugriff (PDF)

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

Blood, 2002-10, Vol.100 (7), p.2367-2373

2002

Volltextzugriff (PDF)

Risk of Psychiatric Disorders in Juvenile Idiopathic Arthritis: Population‐ and Sibling‐Controlled Cohort and Cross‐Sectional Analyses

ACR open rheumatology, 2023-05, Vol.5 (5), p.277-284

2023

Volltextzugriff (PDF)

Diagnostic challenges for a novel SH2D1A mutation associated with X‐linked lymphoproliferative disease

Pediatric blood & cancer, 2020-04, Vol.67 (4), p.e28184-n/a

2020

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(33)
Buchkapitel
(2)

Sprache

Englisch
(35)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(30)
Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(20)
Child
(14)
Female
(14)
Male
(14)
Hematology
(11)
Adolescent
(10)
Child, Preschool
(10)
Pediatrics
(10)
Rheumatology
(9)
Patients
(7)
Arthritis
(6)
Infant
(6)
Biological And Medical Sciences
(5)
Disease
(5)
Hemophagocytic Lymphohistiocytosis
(5)
Lymphohistiocytosis, Hemophagocytic - Diagnosis
(5)
Medical Sciences
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Expression of concern to: High systematic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

Juvenile idiopathic arthritis, marriage and parenthood: a nationwide matched cohort study

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration

A Two-to-Five Year Follow-Up of a Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort

How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

Population‐based study of multisystem inflammatory syndrome associated with COVID‐19 found that 36% of children had persistent symptoms

Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis

Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

Risk of Psychiatric Disorders in Juvenile Idiopathic Arthritis: Population‐ and Sibling‐Controlled Cohort and Cross‐Sectional Analyses

Diagnostic challenges for a novel SH2D1A mutation associated with X‐linked lymphoproliferative disease

Suchergebnisse filtern